: Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4-5) mRNA vaccine 7-90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4-6 months earlier indicated no significant additional protection (10%; 95% CI: -44 to 44). A second booster vaccination 6 months after the latest infection may be warranted.
Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022 / Fabiani, Massimo; Mateo-Urdiales, Alberto; Sacco, Chiara; Fotakis, Emmanouil Alexandros; Rota, Maria Cristina; Petrone, Daniele; Bressi, Marco; Del Manso, Martina; Siddu, Andrea; Fedele, Giorgio; Stefanelli, Paola; Bella, Antonino; Riccardo, Flavia; Palamara, Anna Teresa; Rezza, Giovanni; Brusaferro, Silvio; Pezzotti, Patrizio. - In: EUROSURVEILLANCE. - ISSN 1560-7917. - 28:8(2023), pp. 1-7. [10.2807/1560-7917.ES.2023.28.8.2300105]
Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022
Petrone, Daniele;
2023
Abstract
: Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4-5) mRNA vaccine 7-90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4-6 months earlier indicated no significant additional protection (10%; 95% CI: -44 to 44). A second booster vaccination 6 months after the latest infection may be warranted.| File | Dimensione | Formato | |
|---|---|---|---|
|
Fabiani_Protection-against-severe-COVID-19_2023.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
226.82 kB
Formato
Adobe PDF
|
226.82 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
